SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...

"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition ...

"The significant improvements observed in AIMS score and the high remission rates highlight the efficacy of INGREZZA, at even the lowest dose." The post-hoc analysis was conducted using data from ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).

(RTTNews) - Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily ingrezza ...

Outstanding Supporting Actress in a Comedy Series Commentary (Updated April 3, 2025): It’s time for Janelle James to stand on the Emmy stage! In her fourth season on ABC’s beloved mockumentary ...

Neurocrine (NBIX) Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA capsules in adults with Huntington ...

Outstanding Lead Actress in a Comedy Series Commentary (Updated April 3, 2025): A mix of returning champions, rising stars, and genre-bending newcomers occupy the lead comedy actress race.